• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

计算和比较复发型神经疾病的年化复发率并估计其置信区间

Calculating and Comparing the Annualized Relapse Rate and Estimating the Confidence Interval in Relapsing Neurological Diseases.

作者信息

Akaishi Tetsuya, Ishii Tadashi, Aoki Masashi, Nakashima Ichiro

机构信息

Department of Education and Support for Regional Medicine, Tohoku University Hospital, Sendai, Japan.

Division of General Medicine, Tohoku University Hospital, Sendai, Japan.

出版信息

Front Neurol. 2022 Jun 10;13:875456. doi: 10.3389/fneur.2022.875456. eCollection 2022.

DOI:10.3389/fneur.2022.875456
PMID:35756930
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9226307/
Abstract

Calculating the crude or adjusted annualized relapse rate (ARR) and its confidence interval (CI) is often required in clinical studies to evaluate chronic relapsing diseases, such as multiple sclerosis and neuromyelitis optica spectrum disorders. However, accurately calculating ARR and estimating the 95% CI requires careful application of statistical approaches and basic familiarity with the exponential family of distributions. When the relapse rate can be regarded as constant over time or by individuals, the crude ARR can be calculated using the person-years method, which divides the number of all observed relapses among all participants by the total follow-up period of the study cohort. If the number of relapses can be modeled by the Poisson distribution, the 95% CI of ARR can be obtained by finding the 2.5% upper and lower critical values of the parameter λ as the mean. Basic familiarity with F-statistics is also required when comparing the ARR between two disease groups. It is necessary to distinguish the observed relapse rate ratio (RR) between two sample groups (sample RR) from the unobserved RR between their originating populations (population RR). The ratio of population RR to sample RR roughly follows the F distribution, with degrees of freedom obtained by doubling the number of observed relapses in the two sample groups. Based on this, a 95% CI of the population RR can be estimated. When the count data of the response variable is overdispersed, the negative binomial distribution would be a better fit than the Poisson. Adjusted ARR and the 95% CI can be obtained by using the generalized linear regression models after selecting appropriate error structures (e.g., Poisson, negative binomial, zero-inflated Poisson, and zero-inflated negative binomial) according to the overdispersion and zero-inflation in the response variable.

摘要

在临床研究中,为评估慢性复发性疾病,如多发性硬化症和视神经脊髓炎谱系障碍,常常需要计算粗年化复发率(ARR)或调整年化复发率及其置信区间(CI)。然而,准确计算ARR并估计95%CI需要谨慎应用统计方法,并对指数分布族有基本的了解。当复发率在时间上或个体间可视为恒定时,可使用人年法计算粗ARR,即将所有参与者观察到的复发总数除以研究队列的总随访期。如果复发数可由泊松分布建模,则可通过将参数λ的2.5%上下临界值作为均值来获得ARR的95%CI。在比较两个疾病组的ARR时,还需要对F统计量有基本的了解。有必要区分两个样本组之间观察到的复发率比(RR)(样本RR)与其总体之间未观察到的RR(总体RR)。总体RR与样本RR的比值大致遵循F分布,其自由度通过将两个样本组中观察到的复发数加倍获得。基于此,可估计总体RR的95%CI。当响应变量的计数数据过度离散时,负二项分布比泊松分布更合适。根据响应变量中的过度离散和零膨胀情况选择适当的误差结构(如泊松、负二项、零膨胀泊松和零膨胀负二项)后,可使用广义线性回归模型获得调整后的ARR和95%CI。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cd31/9226307/9a1d65e0c767/fneur-13-875456-g0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cd31/9226307/6dfa4a0f719b/fneur-13-875456-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cd31/9226307/c09288ecbfec/fneur-13-875456-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cd31/9226307/0fe6dae8071a/fneur-13-875456-g0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cd31/9226307/ab4c82ed9e33/fneur-13-875456-g0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cd31/9226307/fcbed05017fa/fneur-13-875456-g0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cd31/9226307/9a1d65e0c767/fneur-13-875456-g0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cd31/9226307/6dfa4a0f719b/fneur-13-875456-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cd31/9226307/c09288ecbfec/fneur-13-875456-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cd31/9226307/0fe6dae8071a/fneur-13-875456-g0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cd31/9226307/ab4c82ed9e33/fneur-13-875456-g0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cd31/9226307/fcbed05017fa/fneur-13-875456-g0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cd31/9226307/9a1d65e0c767/fneur-13-875456-g0006.jpg

相似文献

1
Calculating and Comparing the Annualized Relapse Rate and Estimating the Confidence Interval in Relapsing Neurological Diseases.计算和比较复发型神经疾病的年化复发率并估计其置信区间
Front Neurol. 2022 Jun 10;13:875456. doi: 10.3389/fneur.2022.875456. eCollection 2022.
2
Clinical and MRI activity as determinants of sample size for pediatric multiple sclerosis trials.临床和 MRI 活动作为儿科多发性硬化症试验样本量的决定因素。
Neurology. 2013 Oct 1;81(14):1215-21. doi: 10.1212/WNL.0b013e3182a6cb9b. Epub 2013 Aug 21.
3
Estimation of sample size in randomized controlled trials in multiple sclerosis studying annualized relapse rates: A systematic review.评估多发性硬化症中研究年化复发率的随机对照试验中的样本量:系统评价。
Mult Scler. 2022 Aug;28(9):1457-1466. doi: 10.1177/13524585211052400. Epub 2021 Oct 26.
4
On performance of parametric and distribution-free models for zero-inflated and over-dispersed count responses.关于零膨胀和过度分散计数响应的参数模型和非参数模型的性能。
Stat Med. 2015 Oct 30;34(24):3235-45. doi: 10.1002/sim.6560. Epub 2015 Jun 15.
5
Analyzing hospitalization data: potential limitations of Poisson regression.分析住院数据:泊松回归的潜在局限性
Nephrol Dial Transplant. 2015 Aug;30(8):1244-9. doi: 10.1093/ndt/gfv071. Epub 2015 Mar 25.
6
Comparative Efficacy and Safety of Ozanimod and Dimethyl Fumarate for Relapsing-Remitting Multiple Sclerosis Using Matching-Adjusted Indirect Comparison.基于匹配调整间接比较的奥扎尼莫德与富马酸二甲酯治疗复发缓解型多发性硬化症的疗效和安全性比较
CNS Drugs. 2021 Jul;35(7):795-804. doi: 10.1007/s40263-021-00805-0. Epub 2021 Apr 13.
7
Placebo cohorts in phase-3 MS treatment trials - predictors for on-trial disease activity 1990-2010 based on a meta-analysis and individual case data.基于荟萃分析和个体病例数据的 1990-2010 年 MS 治疗三期试验中的安慰剂队列-试验期间疾病活动的预测因子。
PLoS One. 2012;7(11):e50347. doi: 10.1371/journal.pone.0050347. Epub 2012 Nov 29.
8
Seasonal patterns of relapse and disability in Danish MS patients: A population-based cohort study.丹麦多发性硬化症患者复发和残疾的季节性模式:一项基于人群的队列研究。
Mult Scler Relat Disord. 2021 Apr;49:102739. doi: 10.1016/j.msard.2021.102739. Epub 2021 Jan 7.
9
Modeling repeated count measures with excess zeros in an epidemiological study.在流行病学研究中对存在过量零值的重复计数测量进行建模。
Ann Epidemiol. 2015 Aug;25(8):583-9. doi: 10.1016/j.annepidem.2015.03.011. Epub 2015 Mar 21.
10
An empirical comparison of methods for analyzing over-dispersed zero-inflated count data from stratified cluster randomized trials.分层整群随机试验中过分散零膨胀计数数据分析方法的实证比较
Contemp Clin Trials Commun. 2020 Feb 1;17:100539. doi: 10.1016/j.conctc.2020.100539. eCollection 2020 Mar.

引用本文的文献

1
The Italian Multiple Sclerosis Register Experience With Cladribine: Impact on Relapses, PIRA, and Treatment Sequencing Strategies Evaluation.意大利多发性硬化症登记处使用克拉屈滨的经验:对复发、PIRA及治疗序列策略评估的影响
Neurol Neuroimmunol Neuroinflamm. 2025 Jul;12(4):e200415. doi: 10.1212/NXI.0000000000200415. Epub 2025 Jun 5.
2
Evaluating natalizumab first-line and later-line use in multiple sclerosis: a US claims database analysis.评估那他珠单抗在多发性硬化症中的一线和二线使用情况:一项美国索赔数据库分析。
Ther Adv Neurol Disord. 2025 Mar 17;18:17562864251317949. doi: 10.1177/17562864251317949. eCollection 2025.
3

本文引用的文献

1
Relapse activity in the chronic phase of anti-myelin-oligodendrocyte glycoprotein antibody-associated disease.抗髓鞘少突胶质细胞糖蛋白抗体相关疾病慢性期的复发活动。
J Neurol. 2022 Jun;269(6):3136-3146. doi: 10.1007/s00415-021-10914-x. Epub 2021 Nov 25.
2
Safety and efficacy of teriflunomide in paediatric multiple sclerosis (TERIKIDS): a multicentre, double-blind, phase 3, randomised, placebo-controlled trial.特立氟胺治疗儿科多发性硬化症的安全性和疗效(TERIKIDS):一项多中心、双盲、III 期、随机、安慰剂对照试验。
Lancet Neurol. 2021 Dec;20(12):1001-1011. doi: 10.1016/S1474-4422(21)00364-1.
3
Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study: A Randomized Clinical Trial.
Long-Term Evaluation of Effectiveness and Immunological Implications of Ocrelizumab in a Real-World Cohort.
奥瑞珠单抗在真实世界队列中的有效性及免疫学影响的长期评估
Drugs Real World Outcomes. 2025 Mar 14. doi: 10.1007/s40801-025-00486-x.
4
Insights into neuromyelitis optica spectrum disorder and pregnancy from a single-center study in Thailand.泰国一项单中心研究对视神经脊髓炎谱系障碍与妊娠的见解。
Sci Rep. 2025 Feb 1;15(1):4011. doi: 10.1038/s41598-025-88624-x.
5
Long-term efficacy and safety of rituximab in the treatment of neuromyelitis Optica Spectrum disorder.利妥昔单抗治疗视神经脊髓炎谱系障碍的长期疗效和安全性。
Mult Scler J Exp Transl Clin. 2024 May 27;10(2):20552173241257876. doi: 10.1177/20552173241257876. eCollection 2024 Apr-Jun.
6
Rituximab treatment in pediatric-onset multiple sclerosis.利妥昔单抗治疗儿童发病多发性硬化。
Eur J Neurol. 2024 May;31(5):e16228. doi: 10.1111/ene.16228. Epub 2024 Feb 20.
7
Statistical evaluation of cluster formation of relapse in neuromyelitis optica spectrum disorder.视神经脊髓炎谱系障碍中复发簇形成的统计学评估。
Neural Regen Res. 2024 Sep 1;19(9):1888-1889. doi: 10.4103/1673-5374.390980. Epub 2023 Dec 15.
8
Moving forward through the in silico modeling of multiple sclerosis: Treatment layer implementation and validation.推进多发性硬化症的计算机模拟建模:治疗层的实施与验证。
Comput Struct Biotechnol J. 2023 May 20;21:3081-3090. doi: 10.1016/j.csbj.2023.05.020. eCollection 2023.
9
Real-world annualized relapse rates from contemporary multiple sclerosis clinics in the UK: a retrospective multicentre cohort study.英国当代多发性硬化症临床实践中的真实世界年度复发率:一项回顾性多中心队列研究。
Neurol Sci. 2023 Oct;44(10):3629-3635. doi: 10.1007/s10072-023-06838-1. Epub 2023 May 20.
10
Impaired response of blood neutrophils to cell-death stimulus differentiates AQP4-IgG-seropositive NMOSD from MOGAD.血中性粒细胞对细胞死亡刺激反应受损将 AQP4-IgG 阳性 NMOSD 与 MO-GAD 区分开来。
J Neuroinflammation. 2022 Oct 1;19(1):239. doi: 10.1186/s12974-022-02600-0.
在主动对照 3 期 OPTIMUM 研究中,与特立氟胺相比,ponesimod 治疗活跃期多发性硬化症的患者:一项随机临床试验。
JAMA Neurol. 2021 May 1;78(5):558-567. doi: 10.1001/jamaneurol.2021.0405.
4
Relapse Patterns in NMOSD: Evidence for Earlier Occurrence of Optic Neuritis and Possible Seasonal Variation.视神经脊髓炎谱系障碍的复发模式:视神经炎更早发生的证据及可能的季节性变化
Front Neurol. 2020 Jun 16;11:537. doi: 10.3389/fneur.2020.00537. eCollection 2020.
5
Safety and efficacy of delayed-release dimethyl fumarate in patients with relapsing-remitting multiple sclerosis: 9 years' follow-up of DEFINE, CONFIRM, and ENDORSE.缓释富马酸二甲酯治疗复发缓解型多发性硬化症患者的安全性和有效性:DEFINE、CONFIRM和ENDORSE研究的9年随访
Ther Adv Neurol Disord. 2020 May 12;13:1756286420915005. doi: 10.1177/1756286420915005. eCollection 2020.
6
Eculizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder.抗水通道蛋白 4 抗体阳性视神经脊髓炎谱系疾病的治疗
N Engl J Med. 2019 Aug 15;381(7):614-625. doi: 10.1056/NEJMoa1900866. Epub 2019 May 3.
7
Comparative effectiveness of teriflunomide and dimethyl fumarate: A nationwide cohort study.来氟米特与富马酸二甲酯的疗效比较:一项全国性队列研究。
Neurology. 2019 Apr 16;92(16):e1811-e1820. doi: 10.1212/WNL.0000000000007314. Epub 2019 Mar 15.
8
Multiple Sclerosis.多发性硬化症
N Engl J Med. 2018 Jan 11;378(2):169-180. doi: 10.1056/NEJMra1401483.
9
Comparative efficacy and discontinuation of dimethyl fumarate and fingolimod in clinical practice at 24-month follow-up.富马酸二甲酯与芬戈莫德在临床实践中24个月随访时的疗效比较及停药情况
Mult Scler J Exp Transl Clin. 2017 Aug 24;3(3):2055217317715485. doi: 10.1177/2055217317715485. eCollection 2017 Jul-Sep.
10
Relapse rates in patients with multiple sclerosis treated with fingolimod: Subgroup analyses of pooled data from three phase 3 trials.用芬戈莫德治疗的多发性硬化症患者的复发率:三项3期试验汇总数据的亚组分析。
Mult Scler Relat Disord. 2016 Jul;8:124-30. doi: 10.1016/j.msard.2016.05.015. Epub 2016 May 24.